All News

malar lupus

Lupus Activity Affects Mortality

d MedPage Today

Each one-unit increase on a disease activity score during the first year after enrollment into a systemic lupus erythematosus (SLE) cohort was associated with a significant increased risk for death and organ damage during subsequent follow-up, researchers reported.

Read Article
RheumNow Podcast square

RheumNow Podcast – Coconspirators: RA and Lung Disease

d Jack Cush, MD

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

Read Article
LBP_0.jpg

Diagnostic Delay in Spondyloarthritis

d Jack Cush, MD

Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.

Read Article
liver.jpg

Increased Methotrexate Liver Disease in Psoriasis

d Jack Cush, MD

A Danish cohort study examined the risk of methotrexate related liver disease risk in patients with psoriasis (PsO)and psoriatic arthritis (PsA), and found that compared to rheumatoid arthritis (RA), psoriatic patients had up to a 3 fold higher risk of liver disease. 

Read Article
MS, multiple, sclerosis, demyelinating, brain, plaque

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy

d Jack Cush, MD

Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy. 

Read Article
lung%2Cbright.jpg

Increased Risk of COPD in ACPA+ Pre-RA Patients

d Jack Cush, MD

The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis.  A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD

Read Article
Lilly has reported clinical success with Baricitinib (JAK inhibitor) in patients with alopecia. Two studies (BRAVE-AA1 and BRAVE-AA2) show statistically significant improvement in scalp hair regrowth with baricitinib compared to placebo. https://t.co/D0GE2cSzDZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for Tuesday Night Rheumatology. This will feature excerpts from: Future Therapies in RA - Dr. Roy Fleischmann Difficult RA - Dr. Maya Buch RA Treatment Paradigms: EULAR 2019 and ACR 2020 Guidelines - Dr. Alan Matsumoto https://t.co/lpOUOqhnIE #RNL2021 #RheumNow https://t.co/9kdaJ3vfSd

Links:

Dr. John Cush RheumNow ( View Tweet)
"Lupus panniculitis appears like this and feels like wood! But... don’t forget about ddx of possible subcutaneous panniculitic T-cell lymphoma. #RNL2021" Thanks Dr. Robert Chao @doctorRBC for the great #RNL2021 coverage.

Dr. John Cush RheumNow ( View Tweet)

News Feature: BSRBR: Demyelinating Disease Following Anti-TNFα Therapy https://t.co/oHJXOa96Kn https://t.co/ucu9AsC8l3

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from Dr. Rachel Tate @uptoTate Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! #RheumNow

Dr. John Cush RheumNow ( View Tweet)

BC, Canada study of Lupus mortality: 6,092 SLE pts followed for 17 yrs, there were 451 deaths. Compared to population, all cause mortality was nearly 2 fold higher (HR 1.85 (1.66-2.06); excess deaths from renal (HR 3.04), INFX (2.74) & CVD (2.05) https://t.co/I0kzXNeulH https://t.co/ZVNp4Ec2gC

Links:

Dr. John Cush RheumNow ( View Tweet)
Diary study of 79 FM, 86 RA, 33 w/ both FM/RA shows that compared to RA, pts with FM have worse daily well-being, negative affect, more isolation, inability to complete plan. FM had more perceived stigma and lower well-being. https://t.co/YZdhvYghuI

Links:

Dr. John Cush RheumNow ( View Tweet)

Sonelokimab is a novel trivalent nanobody aimed at IL-17A & IL-17F; tested at multiple doses vs Placebo or secukinumab in 383 plaque psoriasis pts: SON at doses 60-120 mg had efficacy similar to SEC; but SON had more Candida infx (17·4% vs 1.9% SEC) https://t.co/Nhh9UyX3i0

Links:

Dr. John Cush RheumNow ( View Tweet)

"Dr. M McMahon distinguishes SLE presentation in different ethnicities. -People of color have > risk for renal dz -Black patients have higher rates of SkM and neuro dz -Death 4X > in Asians, 6X > in Hispanics #RNL2021 " #RNL2021 coverage from @KDAO2011

Dr. John Cush RheumNow ( View Tweet)

News Feature: Increased Risk of COPD in ACPA+ Pre-RA Patients A new study shows that elevation of ACPAs before diagnosis of RA increases the risk of developing COPD and/or asthma. https://t.co/1F8fOxpaQ0 https://t.co/GaaGcF90YD

Links:

Dr. John Cush RheumNow ( View Tweet)
When DOACs (Xarelto, Eliquis) used for Afib or VTE, concomitant aspirin also given (without indication) in 34%. There was no additional anti-thrombotic effect, PLUS ASA use adds 20% increased risk of non-major bleeding. Registry cohort study of 3280 pts. https://t.co/6vDw8HfDZX

Links:

Dr. John Cush RheumNow ( View Tweet)

2016 FDA labeling discourage quinolones (tendinopathy, interstitial nephitis) use. Since QUIN Rx have steadily dropped for UTI, sinusitis & COPD with shift to nitrofurantoin, amoxil, macrolides & tetracyclines. Still QUIN used in 15-19% of UTIs and COPD https://t.co/Yq2c8YFUog

Links:

Dr. John Cush RheumNow ( View Tweet)

Did you miss yesterday's Tuesday Night Rheumatology? Watch the replay and see how we answered questions from the webinar attendees. https://t.co/WnnUklOmMP https://t.co/o2mRNZrUv8

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: New Side Effect From mRNA COVID Vaccines? Herpes zoster reactivation following COVID-19 vaccination in 6 patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine. https://t.co/GgjoIpYDkC https://t.co/sI2Fx0o05G

Links:

Dr. John Cush RheumNow ( View Tweet)
×